Foghorn Therapeutics (FHTX) Income towards Parent Company (2020 - 2025)
Historic Income towards Parent Company for Foghorn Therapeutics (FHTX) over the last 6 years, with Q3 2025 value amounting to -$16.5 million.
- Foghorn Therapeutics' Income towards Parent Company rose 1387.41% to -$16.5 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$75.0 million, marking a year-over-year increase of 1780.47%. This contributed to the annual value of -$86.6 million for FY2024, which is 1199.48% up from last year.
- Per Foghorn Therapeutics' latest filing, its Income towards Parent Company stood at -$16.5 million for Q3 2025, which was up 1387.41% from -$18.8 million recorded in Q2 2025.
- Foghorn Therapeutics' Income towards Parent Company's 5-year high stood at -$14.3 million during Q3 2023, with a 5-year trough of -$30.5 million in Q1 2023.
- Moreover, its 5-year median value for Income towards Parent Company was -$24.1 million (2023), whereas its average is -$23.8 million.
- In the last 5 years, Foghorn Therapeutics' Income towards Parent Company crashed by 6890.29% in 2021 and then skyrocketed by 4433.23% in 2023.
- Over the past 5 years, Foghorn Therapeutics' Income towards Parent Company (Quarter) stood at -$28.5 million in 2021, then dropped by 1.33% to -$28.9 million in 2022, then increased by 16.55% to -$24.1 million in 2023, then increased by 19.09% to -$19.5 million in 2024, then increased by 15.56% to -$16.5 million in 2025.
- Its Income towards Parent Company was -$16.5 million in Q3 2025, compared to -$18.8 million in Q2 2025 and -$20.2 million in Q1 2025.